Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors DOI Open Access
Jelena Dinić, Miodrag Dragoj, Sofija Jovanović Stojanov

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 1984 - 1984

Published: May 23, 2024

The impact of tyrosine kinase inhibitors (TKIs) on multidrug resistance (MDR) in non-small cell lung carcinoma (NSCLC) is a critical aspect cancer therapy. While TKIs effectively target specific signaling pathways cells, they can also act as substrates for ABC transporters, potentially triggering MDR. aim our study was to evaluate the response 17 patient-derived NSCLC cultures 10 commonly prescribed and correlate these responses with patient mutational profiles. Using an ex vivo immunofluorescence assay, we analyzed expression MDR markers ABCB1, ABCC1, ABCG2, correlated data genetic profiles patients functional diagnostic approach. responded differently TKIs, erlotinib showing good efficacy regardless mutation burden or EGFR status. However, modulation mechanisms by erlotinib, such increased ABCG2 expression, highlights challenges associated treatment. Other showed limited efficacy, highlighting variability NSCLC. Genetic alterations drug sensitivity, including TP53 mutations, likely contributed variable TKIs. relationships between transporter gene alterations, did not show consistent patterns. Our results suggest that addition status, performing sensitivity screening identifying appropriate treatment strategies These underscore importance considering off-target effects, risks, patient-specific when optimizing highlight potential personalized approaches, especially early stages.

Language: Английский

Overcoming cancer chemotherapy resistance by the induction of ferroptosis DOI
Yumin Wang,

Xiaorui Wu,

Ren Zhao

et al.

Drug Resistance Updates, Journal Year: 2022, Volume and Issue: 66, P. 100916 - 100916

Published: Dec. 29, 2022

Language: Английский

Citations

168
Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications DOI Creative Commons

Xuehao Zhou,

Xiang Ao,

Zhaojun Jia

et al.

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Aug. 17, 2022

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with potential effectively extend patient survival. However, development drug resistance seriously limits clinical efficiency ultimately results in treatment failure death. A large number studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long RNAs, circular are widely involved regulation resistance. Their dysregulation contributes by modulating expression specific target genes cellular apoptosis, autophagy, efflux, epithelial-to-mesenchymal transition (EMT), stem cells (CSCs). Moreover, some ncRNAs also possess great as efficient, biomarkers diagnosis prognosis well targets patients. In this review, we summarize recent findings on emerging role underlying mechanisms focus their applications treatment. This information will be benefit early prognostic assessments ncRNA-based strategies

Language: Английский

Citations

79
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells DOI Open Access
Pankaj Garg, Jyoti Malhotra, Prakash Kulkarni

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2478 - 2478

Published: July 7, 2024

The rise of drug resistance in cancer cells presents a formidable challenge modern oncology, necessitating the exploration innovative therapeutic strategies. This review investigates latest advancements overcoming mechanisms employed by cells, focusing on emerging modalities. intricate molecular insights into resistance, including genetic mutations, efflux pumps, altered signaling pathways, and microenvironmental influences, are discussed. Furthermore, promising avenues offered targeted therapies, combination treatments, immunotherapies, precision medicine approaches highlighted. Specifically, synergistic effects combining traditional cytotoxic agents with molecularly inhibitors to circumvent pathways examined. Additionally, evolving landscape immunotherapeutic interventions, immune checkpoint adoptive cell is explored terms bolstering anti-tumor responses evasion mechanisms. Moreover, significance biomarker-driven strategies for predicting monitoring treatment underscored, thereby optimizing outcomes. For future direction paradigms, current focused prevailing challenges improving patient outcomes, through an integrative analysis these

Language: Английский

Citations

40
Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role DOI

Sandra Kannampuzha,

Abilash Valsala Gopalakrishnan

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(9)

Published: Aug. 7, 2023

Language: Английский

Citations

26
Epigenetic Modulators as Therapeutic Agents in Cancer DOI Open Access

Eshaan Patnaik,

Chikezie O. Madu, Yi Lü

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14964 - 14964

Published: Oct. 6, 2023

Epigenetics play a crucial role in gene regulation and cellular processes. Most importantly, its dysregulation can contribute to the development of tumors. Epigenetic modifications, such as DNA methylation histone acetylation, are reversible processes that be utilized targets for therapeutic intervention. inhibitors disrupt patterns by inhibiting methyltransferases. Such restore normal expression patterns, they effective against various forms cancer. Histone deacetylase increase acetylation levels, leading altered expressions. Like inhibitors, methyltransferase target molecules involved methylation. Bromodomain extra-terminal domain proteins expression. They oncogene inducing anti-proliferative effects seen Understanding epigenetic modifications utilizing will offer new possibilities cancer research.

Language: Английский

Citations

25
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance DOI Creative Commons
Hongquan Wang, Joshua S. Fleishman,

Sihang Cheng

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Aug. 27, 2024

Abstract The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, unique type regulated cell death, plays pivotal role inhibiting tumour growth, presenting new opportunities treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine vulnerability to ferroptosis. In this review, we first summarize the growth/development. Then, core molecular mechanisms ferroptosis, its upstream regulation, and downstream effects on Finally, review recent advances understanding how ncRNAs regulate ferroptosis from such modulate This aims enhance general ncRNA-mediated regulatory which highlighting ncRNA-ferroptosis axis as key druggable target overcoming

Language: Английский

Citations

15
A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance DOI Creative Commons
Chandrima Das, Apoorva Bhattacharya, Swagata Adhikari

et al.

Oncogene, Journal Year: 2024, Volume and Issue: 43(23), P. 1727 - 1741

Published: May 8, 2024

Abstract Epigenetic regulation established during development to maintain patterns of transcriptional expression and silencing for metabolism other fundamental cell processes can be reprogrammed in cancer, providing a molecular mechanism persistent alterations phenotype. Metabolic deregulation reprogramming are thus an emerging hallmark cancer with opportunities classification as critical preliminary step precision therapeutic intervention. Yet, acquisition therapy resistance against most conventional treatment regimens coupled tumor relapse, continue pose unsolved problems healthcare, exemplified breast where existing data informs both genotype Furthermore, epigenetic reprograming the metabolic milieu cells is among crucial determinants relapse. Importantly, subtype-specific epigenetic-metabolic interplay profoundly affects malignant transformation, chemotherapy, response targeted therapies. In this review, we therefore prismatically dissect interconnected regulatory pathways then integrate them into observable metabolism-therapy-resistance axis that may inform clinical Optimally coupling genome-wide analysis understanding elements, reprogramming, their integration by profiling decode missing mechanisms at level individual tumors. The proposed approach linking biochemistry back genotype, epigenetics, phenotype specific tumors microenvironment enable successful mechanistic targeting modifiers oncometabolites despite heterogeneity.

Language: Английский

Citations

10
Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers DOI Creative Commons
Nooshafarin Shirani,

N. Abdi,

Matin Chehelgerdi

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 24, 2025

Exosomes, as key mediators of intercellular communication, have been increasingly recognized for their role in the oncogenic processes, particularly facilitating drug resistance. This article delves into emerging evidence linking exosomal lncRNAs to modulation resistance mechanisms cancers such ovarian, cervical, and endometrial cancer. It synthesizes current research findings on how these influence cancer cell survival, tumor microenvironment, chemotherapy efficacy. Additionally, review highlights potential therapeutic strategies targeting lncRNAs, proposing a new frontier overcoming By mapping interface resistance, this aims provide comprehensive understanding that could pave way innovative treatments improved patient outcomes female reproductive system cancers.

Language: Английский

Citations

1
Targeting ferroptosis in gastric cancer: Strategies and opportunities DOI

Jiahan Le,

Guangzhao Pan,

Che Zhang

et al.

Immunological Reviews, Journal Year: 2023, Volume and Issue: 321(1), P. 228 - 245

Published: Oct. 30, 2023

Summary Ferroptosis is a novel form of programmed cell death morphologically, genetically, and biochemically distinct from other pathways characterized by the accumulation iron‐dependent lipid peroxides oxidative damage. It now understood that ferroptosis plays an essential role in various biological processes, especially metabolism iron, lipids, amino acids. Gastric cancer (GC) prevalent malignant tumor worldwide with low early diagnosis rates high metastasis rates, accounting for its relatively poor prognosis. Although chemotherapy commonly used to treat GC, drug resistance often leads therapeutic outcomes. In last several years, extensive research on has highlighted significant potential GC therapy, providing promising strategy address associated standard therapies. this review, we offer summary key regulatory factors related mechanisms underlying ferroptosis. Various inducers inhibitors specifically targeting are uncovered. Additionally, explore prospective applications outcomes these agents field emphasizing their capacity improve patient population.

Language: Английский

Citations

22
Nanomedicines for Overcoming Cancer Drug Resistance DOI Creative Commons
Tingting Hu,

Hanlin Gong,

Jiayue Xu

et al.

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(8), P. 1606 - 1606

Published: Aug. 1, 2022

Clinically, cancer drug resistance to chemotherapy, targeted therapy or immunotherapy remains the main impediment towards curative therapy, which leads directly treatment failure along with extended hospital stays, increased medical costs and high mortality. Therefore, increasing attention has been paid nanotechnology-based delivery systems for overcoming in cancer. In this respect, novel tumor-targeting nanomedicines offer fairly effective therapeutic strategies surmounting various limitations of immunotherapy, enabling more precise treatment, convenient monitoring agents, as well resistance, including multidrug (MDR). Nanotechnology-based systems, liposomes, polymer micelles, nanoparticles (NPs), DNA nanostructures, enable a large number properly designed nanomedicines. paper, we review different mechanisms discuss latest developments resistance.

Language: Английский

Citations

28